June 9, 2020
Vanderbilt, AstraZeneca collaborate on new COVID-19 antibody research
After evaluating the ability of more than 1,500 monoclonal antibodies to bind and neutralize the COVID-19 virus, SARS-CoV-2, in the laboratory, AstraZeneca signed an exclusive license to six candidate antibodies in Vanderbilt’s portfolio.
By Bill Snyder